Metropolis Healthcare Q4 FY26 Update: Revenue Jumps 23%, Driven by Specialty and Wellness Segments

Metropolis Healthcare Ltd. reported strong Q4 FY26 results, with consolidated revenues growing 23% year-on-year. This growth was driven by its wellness (TruHealth) and specialty testing segments, which saw gains of 25% and 29% respectively. The company’s B2C channel grew 19% year-on-year, while the B2B segment saw a significant 30% increase, reflecting strong demand.

Organic revenue growth, excluding recent acquisitions, reached approximately 14.5% year-on-year, underscoring the strength of its existing operations.

Key Financial and Operational Strengths

These results highlight Metropolis Healthcare's expansion, fueled by both organic demand and effective acquisition integration. The company's success in wellness and specialty testing signals a strategic move towards higher-margin services. Integration of recent acquisitions is also yielding results, with margins in the Core Diagnostics division now in the high single-digit range, pointing to operational efficiencies.

Strategic Acquisitions Fueling Expansion

Metropolis Healthcare has pursued expansion through a series of strategic acquisitions, including Core Diagnostics (late 2024), Scientific Pathology in Agra (March 2025), Dr. Ahuja's Pathology in Dehradun (April 2025), and Ambika Pathology in Kolhapur (September 2025). The acquisition of Core Diagnostics, a high-end cancer diagnostics player, for ₹247 crore, was particularly important for its North India presence and oncology offerings. Management expects Core Diagnostics' margins to reach double digits by the end of FY26 and align with Metropolis's overall profile within three years, crucial for unlocking synergies.

Outlook and Investor Focus

The Q4 FY26 update suggests Metropolis Healthcare is positioned for sustained strong revenue growth into FY27. Investors will watch for continued progress in integrating new businesses and realizing synergies. The company's diverse revenue streams, strong performance across segments, and network expansion via acquisitions provide a balanced base for future profitability.

Potential Risks

The company's update did not mention any material risks. Metropolis Healthcare has a history of minimal regulatory concerns, with a past complaint filed with the CCI in 2015 having been dismissed.

Competitive Landscape

Metropolis Healthcare's 23% consolidated revenue growth in Q4 FY26 stands out. For comparison, Dr. Lal PathLabs reported 10.6% YoY revenue growth in Q3 FY26 with full-year guidance of 11-12%. Vijaya Diagnostic Centre achieved 21.4% YoY growth in Q3 FY26. The overall Indian pathology lab services market is projected to grow at a compound annual growth rate (CAGR) of 9.37% until 2034.

Market Context

The Indian pathology lab services market is forecast to reach USD 45.4 billion by 2034, expanding at a CAGR of 9.37% between 2026 and 2034. For recent performance context, Metropolis reported ₹406 crore in consolidated revenue for Q3 FY26, a 26% year-on-year increase.

Looking Ahead

Investors will be looking for the Board of Directors' approval of the detailed Q4 FY26 financial statements for a full view of profitability. Continued updates on acquisition integration, the sustainability of organic growth, margin improvements in Core Diagnostics, and any new capex or expansion plans will be key.